^
Association details:
| Biomarker: | SND1-BRAF fusion |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Mekinist (trametinib) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MEK inhibitor sensitivity in BRAF fusion-driven prostate cancer
Published date:
08/22/2022
Excerpt:
...we present the clinical outcome and an in-deep molecular analysis performed in a case harboring a SND1-BRAF fusion gene. The identification of such rearrangement in a patient refractory to standard therapies led to the administration of trametinib (MEK inhibitor). Despite unsensitive to standard therapies, the patient achieved a dramatic response to trametinib.
DOI:
https://doi.org/10.1007/s12094-022-02916-6
